Retatrutide
Triple agonist hitting GIP, GLP-1, and glucagon receptors at once. Phase 2 data shows the largest weight-loss numbers ever reported for a drug in trials. ~24% at 48 weeks.
Choose an option
- Pay with Bitcoin
- Discreet shipping within Germany
- Purity-guaranteed batches
- 14-day refund period if unsatisfied
Delivery & guarantee
Orders typically arrive within 3 weeks.
If your delivery arrives late, you'll receive a discount on your next order.
About
Retatrutide (Eli Lilly's LY3437943) is the next-generation incretin: the GIP and GLP-1 arms do what Tirzepatide does, and the third arm activates glucagon receptors to raise resting energy expenditure. Where GLP-1 alone shrinks intake, glucagon pushes output, which is why the trial numbers come in higher.
Read the full research guideWhy people choose it
- Phase 2 weight loss of ~24% at 12 mg over 48 weeks. Substantially larger than any approved drug
- The curve had not plateaued at 48 weeks, suggesting longer trials may show more
- Glucagon arm raises resting energy expenditure, partially offsetting metabolic adaptation to dieting
- Effective in users who have plateaued on Tirzepatide or maxed out Semaglutide
At a glance
- Experience level
- Advanced
- Administration
- Subcutaneous
Sold for laboratory research only. Not for human consumption. No therapeutic claims are made.
Sign in to view this product
Retatrutide
Log in or create a free account to see full details and prices.
Don't have an account? Sign up